Phase I trial of bruceantin

Area of Science:

• Pharmacology and Toxicology
• Medical Oncology

Background:

• Bruceantin is a chemotherapy agent investigated for treating advanced solid tumors and hematologic neoplasms.
• Understanding its toxicity profile and potential efficacy is crucial for clinical application.

Purpose of the Study:

• To evaluate the safety, tolerability, and preliminary antitumor activity of bruceantin in patients with advanced malignancies.
• To determine a recommended dose for future phase II clinical trials.

Main Methods:

• Thirty-three patients with advanced solid tumors or hematologic neoplasms received bruceantin via intravenous (IV) infusion.
• Treatment involved weekly injections for four weeks, followed by a two-week break, repeated every six weeks.
• Dose escalation ranged from 0.8 to 8.5 mg/m², with toxicity and antitumor response monitored.

Main Results:

• Dose-limiting toxicity was observed as hypotension at doses ≥ 6.0 mg/m², and transient febrile reactions were dose-related.
• Gastrointestinal toxicity was common but not dose-limiting; no hematologic or renal toxicity was noted.
• Hepatic toxicity was subclinical and reversible. Antitumor responses included one partial regression and one disease stabilization.

Conclusions:

• Bruceantin exhibits dose-related hypotension and gastrointestinal toxicity, with no significant hematologic or renal adverse effects.
• A starting dose of 5.5 mg/m² weekly for four weeks, as a 4-hour IV infusion repeated every six weeks, is recommended for phase II studies.